EXTH-15. TESEVATINIB MONOTHERAPY EFFICACY AGAINST GBM12 IS ROBUST IN VITRO BUT RELATIVELY MODEST IN THE INTRACRANIAL GBM12 MODEL, DESPITE EXCELLENT BRAIN PENETRATION | Zendy

AI Assistant Blog Pricing

EXTH-15. TESEVATINIB MONOTHERAPY EFFICACY AGAINST GBM12 IS ROBUST IN VITRO BUT RELATIVELY MODEST IN THE INTRACRANIAL GBM12 MODEL, DESPITE EXCELLENT BRAIN PENETRATION

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.